Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 7/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | EDNRA | P25101 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | HBB | P68871 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.44 |
| ▸ | HPRT1 | P00492 | 3/20 | 0.39 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.36 |
| ▸ | POLG | P54098 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Desciclovir SCHEMBL29403096 | 1.00 | PNP (0.52) | PNPHSD17B10USP2TSHREDNRA | |
| SCHEMBL11001378 | 0.92 | HSD17B10 (0.46) | PNPHSD17B10USP2TSHREDNRA | |
| Desciclovir SCHEMBL28719436 | 0.90 | PNP (0.50) | PNPHSD17B10USP2TSHREDNRA | |
| SCHEMBL8933938 | 0.87 | HSD17B10 (0.52) | PNPHSD17B10USP2TSHREDNRA | |
| SCHEMBL10650936 | 0.87 | HSD17B10 (0.45) | PNPHSD17B10USP2TSHREDNRA | |
| SCHEMBL4255333 | 0.82 | HSD17B10 (0.49) | PNPHSD17B10USP2TSHREDNRA | |
| SCHEMBL8926305 | 0.82 | HSD17B10 (0.61) | PNPHSD17B10USP2TSHREDNRA | |
| SCHEMBL10528638 | 0.81 | HSD17B10 (0.49) | PNPHSD17B10USP2TSHREDNRA | |
| SCHEMBL3151968 | 0.80 | KDM4E (0.55) | HSD17B10KDM4EALDH1A1HPGDADRA1A | |
| SCHEMBL10997155 | 0.79 | HDAC6 (0.43) | HSD17B10TSHRKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1915 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2026-05-28 | — | — | US | claimed |
| WO-2026043843-A1 | TETRAHYDROPYRIMIDINE (THP) IONIZABLE LIPIDS FOR EFFICIENT MRNA DELIVERY | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, (US) | 2026-02-26 | — | — | WO | claimed |
| WO-2025076059-A1 | ROCAGLATE DERIVATIVES AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2025-04-10 | — | — | WO | claimed |
| WO-2025034898-A1 | GASTRIC CANCER PATIENT CLASSIFICATION AND METHODS OF TREATMENT | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-02-13 | — | — | WO | claimed |
| WO-2024215771-A1 | SUBSTITUTED PHENYL ETHYNYL PYRIMIDINES AS POTENT INHIBITORS OF ALPHAVIRUSES | SOUTHERN RESEARCH INSTITUTE (US) | 2024-10-17 | — | — | WO | claimed |
| US-20240139325-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2024-05-02 | — | — | US | claimed |
| EP-4262812-A1 | 6-AZA-NUCLEOSIDE PRODRUGS AS ANTIVIRAL AGENTS FOR TREATING VIRUS INFECTIONS | Southern Research Institute (US) | 2023-10-25 | — | — | EP | claimed |
| WO-2023122212-A2 | SUBSTITUTED PHENYL ETHYNYL PYRIDINE CARBOXAMIDES AS POTENT INHIBITORS OF SARS VIRUS | SOUTHERN RESEARCH INSTITUTE (US) | 2023-06-29 | — | — | WO | claimed |
| CN-115916175-A | Novel 2-pyrimidinone analogs as potent antiviral agents against alphaviruses | 南方研究院 | 2023-04-04 | — | — | CN | claimed |
| EP-4125845-A1 | NOVEL 2-PYRIMIDONE ANALOGS AS POTENT ANTIVIRAL AGENTS AGAINST ALPHAVIRUSES | Southern Research Institute (US) | 2023-02-08 | — | — | EP | claimed |
| EP-0235931-B1 | ANTIVIRAL COMBINATION | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-07-11 | — | — | EP | claimed |
| EP-0158847-B1 | ANTIVIRAL PURINE DERIVATIVES | THE WELLCOME FOUNDATION LIMITED (GB) | 1988-04-20 | — | — | EP | claimed |
| EP-0108285-B1 | ANTIVIRAL PURINE DERIVATIVES | THE WELLCOME FOUNDATION LIMITED (GB) | 1988-04-20 | — | — | EP | claimed |
| EP-0235931-A1 | Antiviral combination | THE WELLCOME FOUNDATION LIMITED (GB) | 1987-09-09 | — | — | EP | claimed |
| EP-0217580-A2 | Therapeutic nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1987-04-08 | — | — | EP | claimed |
| US-4649140-A | 6-DEOXYACYCLOVIR, VIRICIDES | BURROUGHS WELLCOME CO. (US) | 1987-03-10 | — | — | US | claimed |
| EP-0158847-A1 | Antiviral purine derivatives | THE WELLCOME FOUNDATION LIMITED (GB) | 1985-10-23 | — | — | EP | claimed |
| EP-0158513-A2 | Antiviral compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1985-10-16 | — | — | EP | claimed |
| EP-0135713-A2 | Antiviral combinations | THE WELLCOME FOUNDATION LIMITED (GB) | 1985-04-03 | — | — | EP | claimed |
| EP-0108285-A2 | Antiviral purine derivatives | THE WELLCOME FOUNDATION LIMITED (GB) | 1984-05-16 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | HAVCR2, NR1H4, NR1H3 | PNP 1440/4885HSD17B10 235/4885USP2 4142/4885 |
| US-20240139325-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | SLC10A1, HAVCR2, HDGF | PNP 706/4885HSD17B10 125/4885USP2 4444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.